Bright Brexit. Telegraph.
SIR
– There could be a huge advantage from Brexit in my research field.
The
Active Implantable Medical Device Directive of 1990 led to a regime in which it
is impossible to make a viable business case to manufacture new implanted
devices to treat small groups of highly disabled patients, such as those with
spinal cord injury; the imposed costs are too high.
Money
is pouring into the research and development pipeline, with the aim of improving
the quality of life of patients and reducing NHS costs, but new products are not
getting to the market and nobody benefits.
If,
after Brexit, we get this right, companies will move here from the EU to develop
and test new devices with proper appraisal of risk and benefit, done with costs
realistic for business.
Professor
Nick Donaldson
University College London
London WC1
University College London
London WC1
